IRWDIronwood Pharmaceuticals, Inc. Class A

LINZESS sales surged 14% as company raised full-year guidance.

Moby summary of Ironwood Pharmaceuticals, Inc.'s Q2 2026 earnings call

Ironwood Pharmaceuticals reported past second-quarter 2026 results showing sales of US$113.04 million versus US$85.24 million a year earlier, with net income rising to US$51.29 million from US$23.6 million and earnings per share from continuing operations doubling to US$0.31 basic and US$0.31 diluted. For the first half of 2026, the company grew sales to US$219.55 million from US$126.38 million and shifted from a loss to a US$92.06 million profit, prompting management to raise full-year 2026...

Ironwood Pharmaceuticals Inc (IRWD) raises full-year 2026 outlook on robust LINZESS performance and promising apraglutide data.

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook. Chief Execu

Ironwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?